Clinical Report: Reevaluating the Standards for Approving New Cancer Therapies

Overview

This report discusses the challenges associated with expedited cancer therapy approvals, particularly through the FDA's Accelerated Approval Program. It highlights the gap in meaningful clinical outcomes for patients.

Background

The approval of new cancer therapies often relies on surrogate endpoints, such as progression-free survival, which may not accurately reflect overall survival or quality of life.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Many anticancer therapies approved via expedited pathways do not demonstrate overall survival benefits within five years.
• 41% of breast cancer drugs approved in the last 20 years showed only modest gains in overall survival.
• Only 60% of drugs granted accelerated approval from 2013 to 2022 included patient-reported outcome measures.
• Patients are willing to accept clinical uncertainty when no alternative therapies exist or when benefits are transformative.
• There is a need for clear communication regarding the evidence supporting expedited approvals.

Clinical Implications

Healthcare professionals should be aware of the limitations of surrogate endpoints in cancer therapy approvals.

Conclusion

Addressing the evidence gaps in cancer therapy approvals is essential to ensure that patients receive treatments that improve their outcomes.

Related Resources & Content

1. The ASCO Post, 2015 -- Clinical Trial System Badly in Need of Overhaul, Say Panelists at Friends-Brookings Conference
2. The ASCO Post, 2024 -- NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
3. The ASCO Post, 2014 -- ASCO Endorses CAP/IASLC/AMP Guidelines for Molecular Testing of Patients With Non–Small Cell Lung Cancer
4. Accelerated Approval – Expedited Program for Serious Conditions | FDA
5. Ongoing | Cancer Accelerated Approvals | FDA
6. The ASCO Post — NCCN Clinical Practice Guidelines: Important Updates for 2012
7. FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer
8. FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
9. Accelerated Approval – Expedited Program for Serious Conditions | FDA
10. Guidance for Industry
11. 8.5x11_Standard_Letterhead
12. Accelerated Approval Program | FDA
13. Ongoing | Cancer Accelerated Approvals | FDA
14. FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma | FDA
15. Withdrawn | Cancer Accelerated Approvals | FDA
16. Advancing Health Through Innovation: New Drug Therapy Approval 2025
17. Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials - PubMed
18. Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis - PubMed
19. Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis - ScienceDirect
20. Meta-analysis of surrogate endpoints for overall survival in extensive-stage small-cell lung cancer - PMC
21. Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies